Medical Mysteries: The student who is slowly ‘turning into stone’
NTU student Raphaella Gautama has a rare condition that causes muscle and tissue to gradually change into bone. Read more at ...
pharmaphorum5d
After FDA setback, Ipsen gets first OK for rare disease drug palovarotene
Health Canada has given the drug a green light – under the Sohonos brand – to treat fibrodysplasia ossificans progressiva (FOP), making it the first treatment for the ultra-rare genetic disorder.
pharmaphorum5y
Ipsen adds Blueprint's FOP rare disease drug to pipeline for $535m
We will continue to develop and deliver valuable treatments for patients around the world living with FOP and other rare diseases. Blueprint also develops cancer drugs – it is developing ...
Business Wire17d
āshibio Doses First Patient in ANDECAL study, a Phase 2/3 Trial of Andecaliximab for Treatment of Fibrodysplasia Ossificans Progressiva (FOP)
“People living with FOP lack adequate treatment options, and dosing of the first participant in the ANDECAL trial is a significant milestone in our mission to address their needs. Andecaliximab ...
Hosted on MSN2mon
Study identifies the main culprit behind flare-ups in a rare genetic disorder
To determine whether these findings may have implications as potential FOP treatments, the researchers employed genetic and pharmacologic approaches to demonstrate the critical contribution of BMP ...
Muncie officers reinstated after court ruling determines department violated FOP contract
The FOP contract gives officers who were first time offenders the option to resign, retire or enter mandatory substance abuse ...
The Bakersfield Californian17d
āshibio Doses First Patient in ANDECAL study, a Phase 2/3 Trial of Andecaliximab for Treatment of Fibrodysplasia Ossificans Progressiva (FOP)
āshibio, a privately held, clinical-stage biotechnology company developing novel therapeutics for the treatment of severe ... ossificans progressiva (FOP). The dosing milestone for andecaliximab ...